ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ACB / forecast
USNA (50) CGC (41) SNDL (48) GLAS (18) ⌘ Pro Terminal →

Aurora Cannabis Inc. (ACB) 12-Month Stock Forecast & Price Target Cone

$4.06 -0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.05

Aurora Cannabis Inc. (ACB) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $252.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Aurora Cannabis Inc. (NASDAQ: ACB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $4.06 (-0.49% 1D, market cap $252.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ACB ranks #245 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACB compare to USNA and CGC in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), ACB carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $265.0M) and CGC (Canopy Growth Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $285.6M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACB?
▼

For Aurora Cannabis Inc. (ACB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #245 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.05 (-0.28%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Cash (12)Whales (9)SEC (13)Macro (11)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-1.7% Base Target
$7 Bull$4 Base$3 Bear
📬 FREE ACB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACB)Realized 20D OHLCV Swing Band: ±7.9%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY ACB SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0.2% FCF Margin ($7.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$4.35-9% Next Q
Q2 (-2Q)
59
Grade C$3.96-1.5% Next Q
Q3 (-1Q)
57
Grade C$3.90+4.1% Next Q
Current
54
Grade D+$4.06-0.7% Hist 90D α
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACB currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.05) and Max Pain ($4.26) forces dealer call-delta covering toward $6.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ACB Position Size: $10,000

Shares at $4.06: 2463.1 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $3.11
$7,660
$-2,340 (-23.4%)
12M Consensus BaseTarget $3.99
$9,828
$-172 (-1.7%)
12M Bull Case BreakoutTarget $6.68
$16,453
+$6,453 (+64.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 6
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$669%B
JP MorganUS Large-Cap ResearchSELL$458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACB)

  • ✓Walkthrough of ACB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ACB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.71%🛡️ HOLDING TREND SUPPORT
2026-11-02O $4.08H $4.08L $4.06C $4.06VOL 510.1K
RES: $4.86SUP: $3.93SMA50: $4.05SMA200: $3.54
$4.82$4.21$3.59$2.98$2.37RES $4.86SUP $3.93$4.062026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACB Butterfly Map → + Track ACB →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACB)

Health Care Rank #245 of 1016 ⚔️ USNA vs ACB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACB vs. USNA, CGC, SNDL, GLAS)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aurora Cannabis Inc. (ACB) ranks #245 by composite RQD confidence (54/100, grade D+) and #544 by equity capitalization ($252.8M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. ACB currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ACB ACTIVE
Aurora Cannabis Inc.
D+ 54/100 — — — -0.49% $252.8M Benchmark Subject
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% -0.21% $265.0M /usna-vs-acb →
CGC
Canopy Growth Corporation
D- 41/100 — — — -3.33% $285.6M /cgc-vs-acb →
SNDL
SNDL Inc.
D 48/100 — — — -4.61% $316.3M /sndl-vs-acb →
GLAS
Glass House Brands Inc. Subordinate Voting Shares
E 18/100 — 42.3% -9.2% -4.39% $200.6M /glas-vs-acb →

2. ACB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Aurora Cannabis Inc. (ACB) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $252.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ACB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Aurora Cannabis Inc. (NASDAQ: ACB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $4.06 (-0.49% 1D, market cap $252.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ACB ranks #245 in composite RQD confidence.

How does ACB compare to USNA and CGC in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), ACB carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $265.0M) and CGC (Canopy Growth Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $285.6M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACB?

For Aurora Cannabis Inc. (ACB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #245 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACB trading relative to its 50-day, 200-day, and 52-week technical levels?

ACB last traded at $4.06 (-0.49% on volume of 807,217 shares), positioning the stock +0.25% above its 50-day simple moving average ($4.05) and +14.69% above its 200-day simple moving average ($3.54). Across its 52-week range of $2.56 to $6.36, ACB sits at the 39.5% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($3.74 to $4.38).

ACB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ACB's 12-month stock price target?

Aurora Cannabis Inc. (ACB) carries a 12-month consensus base price target of $3.99 (-1.7% from $4.06), with a bull-case target of $6.68 and a bear-case floor of $3.11.

Is ACB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ACB D+ (Sell — SELL) with an RQD Confidence score of 54/100.

Direct Sub-Reports: ACB RQD Cockpit ACB 12M Forecast ACB Earnings & Move ACB Dividends & DRIP ACB Insiders & 13F ACB Whale Options ACB Profit Sankey ACB News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ACB — Aurora Cannabis Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:17:06Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ACB scores 54 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

  • Fundamental Cash Engine (12/20): Reported as ROIC 0% and FCF yield 0%. Per the market data section, the company shows 0% gross, operating, and net margins. For a prospective investor, this pillar indicates no measurable cash generation in the source data to anchor valuation.
  • Whale 13F Flow (9/20): Institutional accumulation and options positioning. The source data does not provide 13F holder detail, so the score is not traceable to specific holders.
  • Insider Conviction (9/20): SEC Form 4 and Congressional PTR cluster flow. The holders section contains no insider transactions, so the score cannot be traced to specific trades.
  • Macro Regime Fit (11/20): Beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity per the market data section; the sector sensitivity detail is not itemized in the source data.
  • Forensic Balance Sheet (13/20): Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5. This is the strongest pillar and suggests a balance sheet that is not in acute distress on these measures, though no financial statements are provided to verify components.

Investment implications: the composite score points to weak fundamentals on the cash-generation pillar, with the balance-sheet pillar offering the main offset. Upside drivers would need to come from catalysts rather than current earnings or cash flow. Valuation tradeoffs are difficult to assess because P/E, EV/EBITDA, and EPS are not available in source data. This is educational analysis, not personalized financial advice.

Business

Aurora Cannabis Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry, per the profile section. The profile describes the company as operating in this industry with a market capitalization of $0.3B. The source data does not itemize product lines, customers, or revenue model.

Recent Catalysts & News Wire Analysis

Per the recent news section, six items relate to ACB. The headlines reference a takeover bid by Curaleaf, with coverage describing an offer to buy the business (Motley Fool), an enhanced offer (Seeking Alpha), and a company response disputing inaccuracies in the bid announcement and citing a "pivotal inflection point" (Stocktwits). A 24/7 Wall St. item notes ACB easing alongside other cannabis names on a day Tilray fell. Several items are tagged as market wire, catalyst, or green/yellow signals, but the source data does not define these labels. Risk watch items include the unresolved status of the takeover bid and the absence of financial detail to evaluate the company's response to it. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are therefore not available in source data. The only sector-level context is the Health Care classification and the Medicinal Chemicals and Botanical Products industry. Investors should watch whether the pending takeover activity described in the news section alters the company's sector positioning, but the source data does not quantify any such ripple.

Open Questions

  • What are the reported revenue, operating income, net income, and free cash flow figures for recent periods, given that the financials section is empty?
  • What are the terms and current status of the Curaleaf takeover bid, and how do they compare with the current price of 4.08?
  • What are the specific 13F holders, Form 4 insider trades, and Congressional PTR filings that support the whale and insider pillar scores?
  • Why are P/E, EV/EBITDA, and EPS unavailable, and what would earnings-based valuation look like?
  • What is the basis for the 0% ROIC and FCF yield figures, and are they representative of current operations?

ACB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aurora Cannabis Inc. (ACB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACB Bull vs. Bear Conversation Board — What's Your Call at $4.06?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACB 🐻 50% BEARISH CONVICTION
1. Pick Your Side on ACB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $4.41 (+8.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ACB (D+ • RQD 54/100) a Buy at $4.08?

Welcome to the ACB (Aurora Cannabis Inc.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.43 (-15.9%)
Spot @ $4.08

Pump the brakes on ACB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ACB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aurora Cannabis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.06 (+24.0%)
Spot @ $4.08

ACB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ACB, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $4.08 (52-wk range $2.56 - $6.36), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%